These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 10391559

  • 1. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
    Kim JA, Bresler HS, Martin EW, Aldrich W, Heffelfinger M, Triozzi PL.
    Cancer; 1999 Jul 01; 86(1):22-30. PubMed ID: 10391559
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
    Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D.
    Br J Cancer; 1999 Nov 01; 81(6):1009-16. PubMed ID: 10576658
    [Abstract] [Full Text] [Related]

  • 3. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 01; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 8. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
    Shetye J, Ragnhammar P, Liljefors M, Christensson B, Frödin JE, Biberfeld P, Mellstedt H.
    Clin Cancer Res; 1998 Aug 01; 4(8):1921-9. PubMed ID: 9717820
    [Abstract] [Full Text] [Related]

  • 9. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z, Fan H, Wu Y, Chen B.
    Cytotherapy; 2005 Aug 01; 7(4):353-62. PubMed ID: 16162457
    [Abstract] [Full Text] [Related]

  • 10. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
    Wadhwa M, Skog AL, Bird C, Ragnhammar P, Lilljefors M, Gaines-Das R, Mellstedt H, Thorpe R.
    Clin Cancer Res; 1999 Jun 15; 5(6):1353-61. PubMed ID: 10389919
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
    J Urol; 2001 Jul 15; 166(1):68-72. PubMed ID: 11435825
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
    van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH.
    Clin Cancer Res; 2005 Mar 01; 11(5):1899-909. PubMed ID: 15756016
    [Abstract] [Full Text] [Related]

  • 18. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
    Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA.
    Cancer; 2003 Jun 15; 97(12):2995-3002. PubMed ID: 12784334
    [Abstract] [Full Text] [Related]

  • 19. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK.
    Dan Med Bull; 2010 Sep 15; 57(9):B4171. PubMed ID: 20816019
    [Abstract] [Full Text] [Related]

  • 20. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.
    Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia SJ.
    J Surg Res; 2005 May 15; 125(2):173-81. PubMed ID: 15854671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.